Counterpoint Mutual Funds’s Axcelis ACLS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
Sell
-726
Closed -$133K 281
2023
Q2
$133K Sell
726
-67
-8% -$9.65K 0.12% 68
2023
Q1
$106K Sell
793
-1,108
-58% -$130K 0.09% 225
2022
Q4
$151K Buy
1,901
+87
+5% +$6.13K 0.16% 91
2022
Q3
$110K Buy
+1,814
New +$117K 0.27% 136
2022
Q2
Sell
-1,188
Closed -$90K 241
2022
Q1
$90K Buy
+1,188
New +$81.2K 0.07% 17
2021
Q4
Sell
-422
Closed -$20K 157
2021
Q3
$20K Buy
+422
New +$18.4K 0.02% 59

Other funds holding ACLS

Counterpoint Mutual Funds's ACLS Position: Q3 2023 in Review

Counterpoint Mutual Funds sold out of Axcelis (ACLS) in Q3 2023, closing a stake of 726 shares — an estimated $133K sold.

Counterpoint Mutual Funds first reported a position in ACLS in Q3 2021 and held it in 6 quarters. The position peaked at $151K in Q4 2022. 420 funds tracked by Wall St. Rank hold ACLS as of Q3 2023.

  • Counterpoint Mutual Funds reported no remaining Axcelis position as of Q3 2023 after selling out during the quarter.
  • Counterpoint Mutual Funds sold 726 Axcelis shares in Q3 2023, an estimated $133K.
  • Counterpoint Mutual Funds first reported a position in Axcelis in Q3 2021 and held it in 6 quarters.
  • Counterpoint Mutual Funds's Axcelis position peaked at $151K in Q4 2022.
  • 420 funds tracked by Wall St. Rank held Axcelis as of Q3 2023.

Based on Counterpoint Mutual Funds's 13F filing for Q3 2023, filed 18 Oct 2023.